![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Pluristem Therapeutics Inc is registered with the U.S. Security and Exchange Commission and incorporated in the state of Nevada. Pluristem Therapeutics Inc is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on June 30th. Th... Pluristem Therapeutics Inc is registered with the U.S. Security and Exchange Commission and incorporated in the state of Nevada. Pluristem Therapeutics Inc is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on June 30th. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Pluristem Therapeutics Inc. Pluristem Therapeutics Inc is a US-based company which acts as a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The lead indications are critical limb ischemia, recovery after surgery for femoral neck fracture, and acute radiation syndrome. The company operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. Show more
HAIFA, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), which transforms cells into solutions that promote...
$10 million funding round from U.S. and EU strategic investors, will accelerate growth and empower efficient cultivated meat, fish and seafood production at global scale, potentially tackling...
As part of Pluri’s previously announced $4.2 million 3-year contract with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), the option for the second year of the contract has...
New production process will be developed based on Pluri’s proprietary 3D cell expansion technologyHuman breast milk oligosaccharides are known to shape the gut microbiota and thus provide health...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.3965 | 7.34259259259 | 5.4 | 6.3499 | 5.35 | 7486 | 5.88927128 | CS |
4 | 0.2965 | 5.39090909091 | 5.5 | 6.72 | 4.556 | 7913 | 5.49444477 | CS |
12 | 0.3365 | 6.163003663 | 5.46 | 6.72 | 4.556 | 9935 | 5.58983007 | CS |
26 | 1.1101 | 23.6876920451 | 4.6864 | 8.48 | 4.16 | 68769 | 6.18618985 | CS |
52 | -0.1235 | -2.08614864865 | 5.92 | 8.56 | 3.4488 | 70906 | 5.64312435 | CS |
156 | -2.2035 | -27.54375 | 8 | 11.5784 | 3.4488 | 67369 | 6.46787191 | CS |
260 | -2.2035 | -27.54375 | 8 | 11.5784 | 3.4488 | 67369 | 6.46787191 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions